Treatments | Targets | Efficacy in R/R DLBCLs | Post CAR-T efficacy | Common toxicities |
---|---|---|---|---|
Pola-BR (GO29365) NCT02257567 | Anti-CD79b/anti-CD20 immunochemotherapy | ORR/CRR, 70% (28/40)/57.5% (23/40) mDOR, 10.3mo mPFS, 7.6 mo mOS, 12.4 mo [29] | ORR/CRR, 72%/33% [283] | Anemia (53.8%), neutropenia (53.8%), thrombocytopenia (48.7%), diarrhea (38.5%), nausea (30.8%), fatigue (35.9%), pyrexia (33.3%), peripheral neuropathy (43.6%) |
Loncastuximab-tesirine | Anti-CD19 immunotherapy | ORR/CRR, 48.3% (70/145)/24.1% (35/145) mDOR, 10.3 mo mPFS, 4.9 mo mOS, 9.9 mo [19] | ORR/CRR, 46.2% (6/13)/15.4% (2/13) Median DOR, 8 mo Median PFS, 1.4 mo Median OS, 8.2 mo [284] | Mild (no adverse events occurred more than 30%) |
Tafasitamab-lenalidomide | Anti-CD19 immunotherapy/ immunomodulation | ORR/CRR 57.5% (46/80)/ 40% (32/80) mDOR, 43.9 mo mPFS, 11.6 mo mOS, 33.5 mo [12] | ORR/CRR, 33%/17% [283] | Neutropenia (49%), anemia (34%), thrombocytopenia (31%), rash (36%), diarrhea (33%) |
Mosenetuzumab (NCT02500407) | T-cell-engaging bispecific antibody | ORR/CRR, 33% (13/39)/ 21% (8/39) [49] | ORR/CRR, 36.8% (7/19)/26.3% (5/19) [50] | Neutropenia (28.4%), cytokine release syndrome (27.4%), hypophosphatemia (23.4%), fatigue (22.8%), diarrhea (21.8%) |
Glofitamab (NCT03075696) | T-cell-engaging bispecific antibody | ORR/CRR, 51.6 (80/155)/39.4% (61/155) [57] | not available | Pyrexia (46.2%), hypotension (24.6%), tachycardia (15.8%), chills (12.3%) |
Odronextamab ≥ 80 mg (NCT02290951) | T-cell-engaging bispecific antibody | ORR/CRR, 60% (6/10)/60% (6/10) [39] | ORR/CRR, 33.3% (7/21)/23.8% (5/21) mDOR, 2.4 mo [39] | pyrexia (76.4%), CRS (62.2%), and chills (48.0%) |
Epcoritamab (NCT03625037) | T-cell-engaging bispecific antibody | ORR/CRR, 63.1% (99/157)/38.9% (61/157) mDOR, 12.0 mo mPFS, 4.4 mo mOS, not reached [54] | ORR/CRR, 54% (33/61)/34% (21/61) [54] | CRS (49.7%), injection site reaction (19.7%), and neutropenia (17.8%) |
Selinexor (NCT02227251) | XPO1 inhibitor | ORR/CRR, 28.3% (36/127)/11.8% (15/127) mPFS 2.6Â months mOS 9.1Â months [213] | Not available | Thrombocytopenia (61%), nausea (58%), fatigue (47%), anaemia (43%), decreased appetite (37%), diarrhoea (35%), constipation (31%), neutropenia (30%), weight loss (30%) |
Allo-SCT | Allogeneic hematopoietic stem cell transplantation | ORR/CRR, 73.9% (17/23)/69.6% (16/23) [266] | Not available | cGVHD at 1Â year (48%) |
Pembrolizumab (49%) Nivolumab (43%) Atezolizumab (6%) Others (2%) | PD-1/PD-L1 | ORR/CRR, 11.8%/7.8% mDOR, 7.5 mo mPFS, 1.8 mo mOS, 4.7 mo [79] | ORR, 33–35% [283] | Cytopenias, infections, pneumonitis, colitis, and hepatotoxicity (no adverse events occurred more than 30%) |
Ibrutinib based | BTK inhibitor | ORR (ABC group), 37% (14/38) ORR (GCB group), 5% (1/20) [157] | ORR/CRR, 38%/25% [283] | Fatigue (40%), diarrhea (38%), nausea (30%) |
Lenalidomide based | Immunomodulation ± immunochemotherapy | ORR/CRR (R2), 28% (9/32)/22% (7/32) [255] | ORR/CRR, 58%/29% [283] | Anemia (88%), neutropenia (100%), thrombocytopenia (94%), leukopenia (91%), lymphopenia (100%), non-neutropenic fever (42%), fatigue (83%), constipation (38%), nausea (43%), neuropathy (58%), blurred vision (31%), myalgia (49%), diarrhea (51%), elevated liver function test (35%), hypocalcemia (30%), raised lactic dehydrogenase (53%), hyperglycemia (47%), hypoalbuminemia (40%), hypophosphatemia (36%) |
R-ICE/R-DHAP | Immunochemotherapy | ORR/CRR, 63%/38% [174] | ORR/CRR, 35%/12% [283] | Grade 3/4 hematologic toxicities were more severe in the R-DHAP, more patients required at least one platelet transfusion during the induction phase (57% in R-DHAP arm v 35% in R-ICE arm) |
Local radiotherapy | Salvage radiotherapy | ORR/CRR, 78.5% (11/14) /57.1% (8/14) [276] | ORR/CRR, 25%/13% [283] | Not available |